In a compelling development showcased at the 63rd European Renal Association (ERA) Congress held in Glasgow, Scotland, the landmark FLOW trial has unveiled profound benefits of once-weekly semaglutide therapy in adults grappling with type 2 diabetes (T2D) and chronic kidney disease (CKD). This pivotal clinical investigation reveals that semaglutide not only mitigates pivotal clinical endpoints but also substantially elevates health-related quality of life (QoL), embodying a transformative advance in the management of this high-risk patient cohort.
The FLOW trial previously documented a remarkable 24% reduction in major kidney disease events and a 20% decline in all-cause mortality over a median treatment period of 3.4 years among participants receiving semaglutide compared to placebo. Moving beyond these tangible clinical outcomes, the latest analysis presented at the congress provides critical patient-centred evidence. It elucidates how semaglutide confers meaningful enhancements in daily functioning and subjective well-being, charting a path toward more holistic therapeutic goals in CKD complicated by T2D.
CKD represents a relentless decline in renal structure or function lasting for at least three months and is intricately linked to diabetes, hypertension, and broader cardio-kidney-metabolic syndromes. Globally, over 850 million individuals live with CKD, a figure that has surged alarmingly since 1990. The disease’s insidious progression elevates risks of kidney failure and premature death, imposing immense physical and psychosocial burdens. Symptoms such as fatigue, pain, and functional impairment alongside treatment side effects exacerbate patients’ quality of life—a metric increasingly recognized as vital alongside traditional clinical targets.
Within the FLOW trial framework, 3,533 adults with T2D and CKD were randomized to receive either semaglutide (1,767 participants) or placebo (1,766 participants). Patient-reported health status was rigorously assessed using the EQ-5D-5L questionnaire, a validated instrument capturing multidimensional aspects of well-being, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. This robust methodology enabled a nuanced evaluation of semaglutide’s impact on subjective health over a follow-up period exceeding two years.
The results are striking. Health utility scores—which quantify health states on a continuum from 0 (death) to 1 (perfect health)—remained stable in the semaglutide group, whereas scores declined in the placebo cohort. The estimated treatment effect of +0.021 (p=0.0001) translates to approximately eight additional days per year experienced in full health. This subtle but statistically robust improvement underscores the drug’s ability to preserve functional status in the face of progressive kidney disease and diabetes complexities.
Complementing these findings, participants’ self-rated general health scores, assessed via a visual analogue scale, progressively improved with semaglutide treatment while deteriorating in the placebo arm. The significant differential of +2.15 points (p<0.0001) further highlights semaglutide’s salutary effects on overall health perception—an important driver of patient satisfaction and adherence in chronic disease management.
Delving deeper, semaglutide demonstrated significant benefits in four out of the five EQ-5D-5L domains: mobility, self-care, usual activities, and pain/discomfort. Notably, no statistically significant effect was observed in the anxiety/depression domain (p=0.55), suggesting that while semaglutide strongly aids physical and functional capacities, its impact on psychological aspects may be limited or require adjunctive interventions. These consistent improvements across functional domains reinforce semaglutide’s utility in preserving autonomy and alleviating symptom burden.
Importantly, the observed quality-of-life enhancements were generally consistent across diverse patient subgroups stratified by age, body mass index (BMI), kidney function, urine albumin-to-creatinine ratio, and cardiovascular history. This broad applicability underscores the drug’s potential as a versatile therapeutic option for a heterogeneous population confronting the dual challenges of T2D and CKD.
Professor Johannes F. E. Mann, the lead investigator from Friedrich Alexander University and McMaster University, expressed measured surprise at the magnitude and breadth of QoL benefits attributable to semaglutide. Despite concerns about commonly encountered gastrointestinal side effects with GLP-1 receptor agonists, the data compellingly suggest that semaglutide’s positive impact on physical functioning and overall well-being outweighs tolerability hurdles, marking a paradigm shift in therapeutic risk-benefit considerations.
The global prevalence and burden of CKD, coupled with its strong association with diabetes-related morbidity, make innovations like semaglutide critically important. Early detection of CKD, combined with interventions that extend beyond biochemical markers to enhance lived patient experiences, represent a frontier in renal medicine. The FLOW trial findings align well with this evolving clinical ethos, emphasizing patient-centred outcome measures alongside traditional endpoints.
Clinicians are thus encouraged to incorporate these insights into shared decision-making processes, recognizing that patients often prioritize quality of life equivalently to longevity gains. The FLOW trial’s evidence base invites nephrologists, endocrinologists, and primary care providers to rethink treatment goals in CKD complicated by T2D, integrating semaglutide’s dual benefits of survival and functional status preservation.
Looking forward, research efforts must intensify to elucidate the precise mechanisms underpinning semaglutide’s ability to maintain and enhance quality of life. Exploring biochemical pathways, metabolic modulation, and interactions with gut-brain axes may unlock further therapeutic optimization. Such investigations could additionally refine strategies to mitigate gastrointestinal adverse effects, amplifying adherence and outcomes.
In sum, the FLOW trial’s latest revelations spotlight once-weekly semaglutide as a robust agent that not only curtails disease progression and mortality but also meaningfully enriches day-to-day patient functioning and perceived health. This holistic therapeutic profile represents a significant leap forward in the treatment paradigm for adults confronting the daunting challenges of type 2 diabetes and chronic kidney disease.
Subject of Research: Effects of semaglutide on quality of life and clinical outcomes in adults with type 2 diabetes and chronic kidney disease.
Article Title: The transformative impact of semaglutide on health-related quality of life in type 2 diabetes with chronic kidney disease: insights from the FLOW trial
News Publication Date: June 2026
Web References: www.era-online.org
References:
1. Mann, J.F.E., Rasmussen, I., Gunnarsson T., et al. (2026). The Effects of Semaglutide on Health-Related Quality of Life in Adults with Type 2 Diabetes and Chronic Kidney Disease: FLOW trial. Abstract ERA26-LBCT-200. Presented at the 63rd ERA Congress, Glasgow, Scotland, June 2026.
2. Perkovic, V., Tuttle, K.R., Rossing, P. et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England Journal of Medicine, 391(2), 109–121.
3. Jager, K. J., Kovesdy, C., Langham, R., et al. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney International, 96(5), 1048–1050.
4. Ortiz, A., Lees, J. S., Torra, R., et al. (2026). The updated global burden of chronic kidney disease: one death every 20 seconds. Nephrology, Dialysis, Transplantation.
5. Kidney Disease: Improving Global Outcomes. (KDIGO) CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4S), S117–S314.
Keywords: chronic kidney disease, type 2 diabetes, semaglutide, GLP-1 receptor agonist, health-related quality of life, FLOW trial, nephrology, clinical outcomes, patient-reported outcomes, kidney disease progression, mortality reduction, quality of life improvement
